Fosaprepitant

Drug Profile

Fosaprepitant

Alternative Names: Emend For Injection; Emend IV; Fosaprepitant dimeglumine; IVEmend; MK-0517; MK-517; ONO-7847; Proemend

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; Ono Pharmaceutical
  • Class Antiemetics; Morpholines; Small molecules
  • Mechanism of Action Neurokinin 1 receptor antagonists; Substance P inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting
  • No development reported Postoperative nausea and vomiting

Most Recent Events

  • 01 Nov 2016 Merck completes a phase-II clinical trial in Chemotherapy induced nausea and vomiting (In children, In infants, In neonates) in USA, Brazil, Canada, Chile, South Korea, Peru, South Africa, the UK, Austria, Estonia, Germany, Greece, Hungary, Italy, Lithuania, Portugal, Romania, Spain, Ukraine and Turkey (IV) (NCT01697579)
  • 18 Mar 2016 Registered for Chemotherapy induced nausea and vomiting (In children, In infants) in Japan (IV)
  • 04 Feb 2016 Merck files sNDA for the approval of fosaprepitant single dose regimen for the prevention of Chemotherapy induced nausea and vomiting associated with emetogenic chemotherapy before February 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top